

ASX Media Release

Allegra receives funding through University of Sydney NHMRC grant

SYDNEY 23rd December 2019 – Allegra Orthopaedics Limited (Allegra) (ASX: AMT) is to receive \$786,000 from the University of Sydney through the National Health and Medical Research Council (NHMRC) Development Grants funding.

In August 2018, the NHMRC awarded the University of Sydney a research grant of \$981,418, with the goal of producing a clinically proven, market-ready, synthetic scaffold material to be used for spinal fusion.

From the success of this grant awarded to the University of Sydney's biomedical engineering department, Allegra will receive \$786,000 to contribute towards the pre-clinical animal study as per FDA requirements (refer ASX announcement 15th November 2019).

The success of this study will lead to a small confirmatory human clinical trial which is to take place in Australia, the final step before commercialization.

Jenny Swain, Allegra Chief Executive Officer, said: *"We are delighted to receive this funding from the University of Sydney through the success of the NHMRC grant. This is a fantastic outcome for the progression of the cervical fusion device project. This funding, which will be targeted specifically for the pre-clinical study, will allow us to mobilise other funds into areas associated with the continued development of this bioceramic material".*

Professor Zreiqat from University of Sydney, said: *"the collaboration and allocation of funds is a crucial step towards putting the research into practice".*

"I could not be happier to see the product we worked on for many years is in the hands of an Australian orthopaedic company. Every researcher's dream is to see their product helping patients and I'm hopeful this technology will have a positive impact on the lives of those requiring spine fusion surgeries

"None of this would have been possible without the generous support of from the Australian Government, whose NHMCR Development Grant will help translate this discovery to the clinic."

Allegra Orthopaedics Limited

Level 8, 18 -- 20 Orion Rd, Lane Cove West NSW 2066 Australia; PO Box 72 St Leonards NSW 2065 Australia

T +612 9119 9200 **T** Toll Free 1800 644 370

F +612 9439 4441 **F** Toll Free 1800 624 223

E sales@allegraorthopaedics.com

www.allegraorthopaedics.com

Authorised by:

Jenny Swain – CEO

Contact details:

Justyn Stedwell – Company Secretary

T: 03 9191 0135

ABOUT ALLEGRA ORTHOPAEDICS

We aim to help bring the freedom and happiness of pain--free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world--wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributors of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventors, including its global licensee to the composite biocompatible ceramic material known as Sr-HT-Gahnite from the University of Sydney.